Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 145 от 154

Активно (без набиране) Фаза 3

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Epithelial Ovarian Cancer Primary Peritoneal Fallopian Tube Cancer Newly Diagnosed +3

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.

Начало: 14.05.2018 Край: 30.12.2030 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +20 pharmaand GmbH NCT03522246

Активно (без набиране) Фаза 3

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer

Начало: 14.05.2018 Край: 03.10.2028 Възраст: 18–130 г. Лечение

Australia, Belgium, Canada +8 AstraZeneca NCT03528694

Активно (без набиране) Фаза 2

PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases

Prostate Cancer Prostate Cancer Metastatic Metastatic Cancer Oligometastatic Cancer

A proportion of prostate cancer (PCa) patients develop relapse following curative local treatment. Regional nodal recurrence is an emerging clinical situation since the introduction of new molecular imaging methods in the restaging of recurrent prostate cancer. More specifically, a subgroup of these patients is being diagnosed with a recurrence confined to the regional lymph nodes and limited in number (oligorecurrence) using choline or PSMA PET-CT. As there are no specific treatment recommendations for these type of patients, different treatment approaches are currently used, mostly focusing on local ablative treatments using radiotherapy or surgery. These treatments are coined metastasisdirected therapy (MDT). MDT in combination with or without temporary ADT could delay the subsequent risk of progression, and even cure limited regional nodal recurrences. Consequently, lifelong palliative ADT, with its toxicity and excess in non-cancer mortality might be postponed. The proposed trial randomizes patients with oligorecurrent nodal prostate cancer following primary PCa treatment to either metastasis-directed therapy (MDT) (salvage lymph node dissection, sLND or stereotactic body radiotherapy, SBRT) or MDT plus whole pelvis radiotherapy (WPRT: 45 Gy in 25 fractions).

Начало: 27.04.2018 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Italy +3 University Hospital, Ghent NCT03569241

Активно (без набиране) Фаза 1

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Selected Advanced Solid Tumors

The purpose of this study is to evaluate MEDI5752 and carboplatin and pemetrexed or paclitaxel or nab-paclitaxel in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.

Начало: 24.04.2018 Край: 30.12.2025 Възраст: 18–120 г. Лечение

Australia, France, Italy +6 MedImmune LLC NCT03530397

Активно (без набиране) Фаза 3

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Non-small Cell Lung Cancer

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery \[neoadjuvant phase\], followed by pembrolizumab alone after surgery \[adjuvant phase\] in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will improve: 1) event free survival (EFS) by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); and 2) overall survival (OS).

Начало: 24.04.2018 Край: 29.06.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 Merck Sharp & Dohme LLC NCT03425643

Активно (без набиране) Фаза 3

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Hepatocellular Carcinoma Liver Cancer

This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence

Начало: 18.04.2018 Край: 27.02.2031 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +21 Bristol-Myers Squibb NCT03383458

Активно (без набиране) Фаза 2

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm Malignant Solid Neoplasm Recurrent Ependymoma Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor +29

This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or does not respond to treatment (refractory) and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Начало: 17.04.2018 Край: 03.10.2026 Възраст: 12–21 г. Лечение

Australia, Canada, Puerto Rico +1 National Cancer Institute (NCI) NCT03213652

Активно (без набиране) Фаза 2/3

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.

Начало: 13.04.2018 Край: 28.01.2028 Възраст: от 18 г. Лечение

Australia, Belarus, Bosnia and Herzegovina +36 Janssen Research & Development, LLC NCT03466411

Активно (без набиране) Фаза 2/3

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

Melanoma

The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.

Начало: 11.04.2018 Край: 15.12.2030 Възраст: от 12 г. Лечение

Argentina, Australia, Belgium +20 Bristol-Myers Squibb NCT03470922

Активно (без набиране) Фаза 1/2

BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

Focal Impaired Awareness Seizures

The purpose of this study is to examine safety signals and demonstrate seizure reduction in adults with FIAS treated with BIS-001ER as an add-on therapy in an in-patient and out-patient study design.

Начало: 10.04.2018 Край: 30.12.2026 Възраст: 18–65 г. Лечение

Australia Supernus Pharmaceuticals, Inc. NCT03474770

Активно (без набиране) Фаза 3

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Crohn's Disease

The study consists of 4 sub-studies, as follows: * Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in participants with moderately to severely active Crohn's disease (CD) who responded to intravenous risankizumab induction treatment in Study M16-006 or Study M15-991; * Sub-study 2 (Randomized, exploratory maintenance study) to evaluate the efficacy and safety of two different dosing regimens for risankizumab as maintenance therapy in participants who responded to induction treatment in Study M16-006 or Study M15-991; * Sub-study 3 (Open-label, long-term extension study) to evaluate long-term safety of risankizumab in participants who completed Sub-study 1, Sub-study 2, another AbbVie risankizumab Crohn's disease study, or participants who responded to induction treatment in Study M16-006 or Study M15-991 with no final endoscopy due to the Covid-19 pandemic. Additional objectives are to further investigate long-term efficacy and tolerability of risankizumab; * Sub-study 4 (Open-label On Body Injector (OBI) administration and long-term extension study) to evaluate patient-reported outcomes, efficacy, safety, tolerability, and pharmacokinetics of risankizumab administered via OBI in participants who are receiving maintenance treatment with risankizumab. * OL CTE to ensure uninterrupted care in accordance with local regulations until risankizumab is commercially available for participants who completed Sub-study 3, Sub-study 4.

Начало: 09.04.2018 Край: 01.05.2026 Възраст: 16–80 г. Лечение

Argentina, Australia, Belarus +39 AbbVie NCT03105102

Активно (без набиране) Фаза 2/3

Urine CXCL10 Monitoring Trial in Kidney Transplant

Kidney Transplant; Complications Rejection of Renal Transplant

This is a Phase II-III multi-center prospective randomized controlled clinical trial of incident adult renal transplant patients. The primary objective of this study is to determine if the early treatment of rejection, as detected by urinary CXCL10, will improve renal allograft outcomes.

Начало: 03.04.2018 Край: 26.09.2025 Възраст: от 18 г. Скрининг

Australia, Canada University of Manitoba NCT03206801

Активно (без набиране) Фаза 2

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Part 1 includes participants with t(11;14) positive relapsed/refractory (R/R) multiple myeloma who will receive venetoclax in combination with daratumumab and dexamethasone (VenDd); Part 2 includes participants with R/R multiple myeloma who will receive venetoclax in combination with daratumumab, bortezomib, and dexamethasone (VenDVd); Part 3 includes participants with t(11;14) positive R/R multiple myeloma who will receive venetoclax in combination with daratumumab and dexamethasone (VenDd) or daratumumab, bortezomib, and dexamethasone (DVd). Part 1 and Part 2 are non-randomized and will be initiated with a dose-escalation phase in which increasing doses of venetoclax will be given with fixed doses of daratumumab and dexamethasone (Part 1a) or with fixed doses of daratumumab, bortezomib, and dexamethasone (Part 2a). Each dose escalation phase will be followed by a single-arm, open-label expansion phase. Part 3 will include a randomized, open-label expansion phase with participants receiving venetoclax in combination with daratumumab and dexamethasone (VenDd) or daratumumab, bortezomib, and dexamethasone (DVd).

Начало: 02.04.2018 Край: 01.05.2031 Възраст: от 18 г. Лечение

Australia, Canada, Denmark +3 AbbVie NCT03314181

Активно (без набиране) Фаза 4

Optimising Rotavirus Vaccine in Aboriginal Children

Viral Gastroenteritis Due to Rotavirus

Australian Indigenous children, particularly those living in remote communities, suffer a disproportionately high burden of rotavirus gastroenteritis disease. Despite the introduction of rotavirus vaccine into the Northern Territory (NT) Immunisation Schedule in 2006, the rate of hospitalization for rotavirus in NT Aboriginal children \< 5 years continues to be high, and the rate ratio of rotavirus hospitalisations for Indigenous versus non-Indigenous children has actually increased. The reasons for sub-optimal vaccine response are not completely understood, but both reduced vaccine immune responses and low vaccine coverage are likely to be important factors. The purpose of this study is to determine if Aboriginal children who receive an additional dose of RV1 between the ages of 6 and 12 months, will have an increase anti-rotavirus serum IgA seroconversion and decreased medical presentations with gastroenteritis in the first three years of life, compared to those who receive placebo.

Начало: 27.03.2018 Край: 01.12.2026 Възраст: 6–12 г. Превенция

Australia Telethon Kids Institute NCT02941107

Активно (без набиране) Фаза 3

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

Urothelial Cancer

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\[L\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).

Начало: 23.03.2018 Край: 31.12.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 Janssen Research & Development, LLC NCT03390504

Активно (без набиране) Фаза 3

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Crohn's Disease

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult participants with Crohn's Disease.

Начало: 21.03.2018 Край: 01.09.2027 Възраст: 18–75 г. Лечение

Argentina, Australia, Belgium +41 AbbVie NCT03345823

Активно (без набиране) Фаза 2

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

Stage IV Prostate Adenocarcinoma AJCC v7

This randomized phase II trial studies how well surgical removal of the prostate and antiandrogen therapy with or without docetaxel work in treating men with newly diagnosed prostate cancer that has spread to other places in the body. Androgens can cause the growth of prostate cancer cells. Antiandrogen therapy may lessen the amount of androgens made by the body. Drugs used in chemotherapy, such as docetaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Surgery, antiandrogen therapy and docetaxel may work better in treating participants with prostate cancer.

Начало: 20.03.2018 Край: 01.03.2027 Възраст: от 18 г. Лечение

Australia, China, Japan +3 Yale University NCT03456843

Активно (без набиране) Фаза 3

The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants

Eczema Asthma Allergy;Food

This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and food allergy in high risk infants. A total of 760 participants with a first degree family history of allergic disease (asthma, eczema, allergic rhinitis or food allergy) will be recruited (380 each group) from maternity wards of three hospitals.

Начало: 06.03.2018 Край: 31.05.2027 Възраст: до 3 г. Превенция

Australia University of Melbourne NCT03667651

Активно (без набиране) Фаза 2

Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

Glioblastoma Multiforme

This study aims to investigate effect of Nivolumab and Temozolomide vs Temozolomide alone on overall survival in newly diagnosed elderly patients with glioblastoma. Who is it for? You may be eligible to join this study if you are aged 65 years or above, with newly diagnosed histologically confirmed GBM (WHO grade IV glioma including gliosarcoma) following surgery. The study aims to evaluate whether the combination of adjuvant nivolumab with temozolomide improves overall survival outcomes for this patient population. The outcome of the study will help determine the most effective treatment for patients with glioblastoma in the future.

Начало: 22.02.2018 Край: 31.12.2025 Възраст: от 65 г. Лечение

Australia, United States University of Sydney NCT04195139

Активно (без набиране)

PARTNER 3 Trial - Mitral Valve in Valve

Mitral Valve Insufficiency Mitral Valve Disease Mitral Valve Regurgitation Heart Failure

To assess the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with a failing mitral bioprosthetic valve.

Начало: 01.02.2018 Край: 01.08.2031 Лечение

Australia, Brazil, United States Edwards Lifesciences NCT03193801

1 … 143 144 145 146 147 … 154